Ceftazidime-Avibactam Use in a Case Series of Difficult-to-Treat or Recurrent Infections in Pediatric Patients with Complex Chronic Conditions: Effectiveness and Absence of Resistance Development

• Egile Nagusiak: Miguel García-Boyano (Egilea), María Alós Díez (Egilea), Lorena Fernández Tomé (Egilea), Luis Escosa-García (Egilea), Francisco Moreno Ramos (Egilea), Cristina Schuffelmann-Gutiérrez (Egilea), Emilio Cendejas Bueno (Egilea), Cristina Calvo (Egilea), Fernando Baquero-Artigao (Egilea), Esteban Frauca Remacha (Egilea)
• Formatua: Liburua
• Argitaratua: MDPI AG, 2024-06-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

The prevalence of multidrug-resistant Gram-negative infections, particularly carbapenem-resistant strains, has become a significant global health concern. Ceftazidime-avibactam (CZA) has emerged as a promising treatment option. However, data on its efficacy and safety in children are scarce, necessi...